Placenta and umbilical cord cell protective solution

A technology of protective solution and umbilical cord, which is applied in the preservation, application, and animal husbandry of human or animal bodies. It can solve the problems of not being able to substantially simulate the human body environment, rapid loss of active substances, and complicated preparation of protective solutions, so as to protect cell activity. , Improving immune function and preventing cell apoptosis

Inactive Publication Date: 2017-09-01
CENTURY BIOSTRENGTH BEIJING PTY LTD
View PDF9 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In order to solve the problem that although the protective solution in the prior art can preserve placental or umbilical cord cells, the preparation of this protective solution is complicated, and the solution stability is poor, and it cannot substantially simulate the human body environment. It can cause problems such as decreased activity of cells during storage, rapid loss of active substances, and easy apoptosis of cells during long-term storage. The invention provides a protective solution for placenta and umbilical cord cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Placenta and umbilical cord cell protective solution

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Embodiment 1 of the present invention provides a protective solution for placenta and umbilical cord cells. The protective solution is mainly formed by dissolving mycoplasma inhibitors and gentamycin in MEM-α medium aqueous solution, and each mL of the MEM-α culture 10 mg of the mycoplasma inhibitor and 180 U of the gentamycin were dissolved in the base aqueous solution, and the concentration of the MEM-α medium aqueous solution was 10 mg / mL.

Embodiment 2

[0028] Embodiment 2 of the present invention provides a protective solution for placenta and umbilical cord cells. The protective solution is mainly formed by dissolving mycoplasma inhibitors, gentamycin and kanamycin with MEM-α medium aqueous solution. The MEM-alpha medium aqueous solution dissolves 20 mg of the mycoplasma inhibitor, 150 U of the gentamycin, and 60 U of the kanamycin respectively, and the concentration of the MEM-alpha medium aqueous solution is 12.5 mg / mL.

Embodiment 3

[0030] Embodiment 3 of the present invention provides a protective solution for placenta and umbilical cord cells. The protective solution is mainly prepared by dissolving mycoplasma inhibitors, gentamicin, amikacin and tobramycin in an aqueous solution of MEM-α medium. 30 mg of the mycoplasma inhibitor, 80 U of the gentamycin, 80 U of the amikacin, 80 U of the tobramycin, and 80 U of the tobramycin were dissolved in each mL of the MEM-α medium aqueous solution, and the MEM-α The concentration of the aqueous medium solution was 15 mg / mL.

[0031] The mycoplasma inhibitor comprises the following components in parts by weight: 20 parts of leucomycin, 10 parts of lysine tetracycline, and 20 parts of gemifloxacin.

[0032] The present invention also provides a kind of preparation method of placenta and umbilical cord cell protection liquid, and this preparation method comprises the following steps:

[0033] S1, get the MEM-α medium aqueous solution that concentration is 15mg / mL, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a placenta and umbilical cord cell protective solution. The protective solution is mainly prepared by dissolving a mycoplasma inhibitor and aminoglycoside antibiotics with an aqueous solution of MEM-alpha medium. 1 mL of the aqueous solution of MEM-alpha medium is respectively used for dissolving 10-30 mg of the mycoplasma inhibitor and 180-240 U of the aminoglycoside antibiotics. Concentration of the aqueous solution of MEM-alpha medium is 10-15 mg/mL. The protective solution provided by the invention not only can effectively kill or inhibit formation of mycoplasma and prevent placenta cell or umbilical cord cell infection, but also can provide a stable osmotic pressure environment for placenta or umbilical cord cells through addition of protective components. Then, human environment can be effectively simulated, and cell survival rate is raised. Meanwhile, nutrients can be provided for storing and transporting cells within a short period of time; immune performance of cells is enhanced; cell infection is prevented; cell viability is effectively improved; and cell transport time is prolonged.

Description

technical field [0001] The invention belongs to the technical field of placenta and umbilical cord cell preservation, in particular to a placenta and umbilical cord cell protection solution. Background technique [0002] In recent years, the upsurge of preserving placental stem cells and umbilical cord blood stem cells has been increasing year by year. Most people already know that using umbilical cord blood stem cells can cure blood system diseases and many other benefits, but little is known about the important uses of placental stem cells in the biomedical field. Preserving the placenta is mainly to extract mesenchymal stem cells from the preserved placenta. The mesenchymal stem cells contained in the placenta are very rich. In addition, placental mesenchymal stem cells can treat a wide range of diseases, such as heart disease, cerebrovascular disease, nervous system disease, liver disease, bone tissue disease, corneal loss, burns, Myopathy and other myopathy; similarly,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01N1/02
CPCA01N1/0215A01N1/0221A01N1/0226
Inventor 李霞云曹毓琳白志惠刘世红卢承前
Owner CENTURY BIOSTRENGTH BEIJING PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap